AllSci News
Acadia secures Fast Track designation for remlifanserin in Alzheimer’s disease psychosis
Acadia Pharmaceuticals has received US FDA Fast Track designation for remlifanserin, an investigational 5-HT2A receptor inverse agonist for Alzheimer’s disease psychosis, as…
BioCytics partners with UNC Charlotte to explore the cancer dark genome
North Carolina-based biotech BioCytics has partnered with UNC Charlotte and Carolina BioOncology Institute to investigate viral and non-coding genomic sequences as potential…
Samsung Biologics expands into peptide manufacturing with USD 1.8b PolyPeptide acquisition
Samsung Biologics (KRX: 207940) has launched an all-cash public tender offer to acquire Switzerland-based PolyPeptide Group AG (SIX: PPGN) at CHF 44.31 per...
BMS expands AI infrastructure deal with NVIDIA as pharma computing race accelerates
Bristol Myers Squibb is expanding its AI infrastructure through a deeper partnership with NVIDIA, deploying DGX SuperPOD systems built on NVIDIA’s Vera…
Tempus acquires Personalis for USD 1.5b to consolidate MRD leadership in precision oncology
Tempus AI, Inc. (Nasdaq: TEM) has agreed to acquire Fremont, California-based Personalis, Inc. (Nasdaq: PSNL) in a transaction valued at $1.5 billion in...
Incyte adds Halozyme's ENHANZE tech to first-in-class myeloproliferative neoplasm therapy
Halozyme Therapeutics (Nasdaq: HALO) has entered a global collaboration and license agreement with Incyte (Nasdaq: INCY) to apply Halozyme's ENHANZE drug...
Pfizer ends development of Seagen-derived mesothelin ADC
Pfizer (NYSE: PFE), through its wholly owned subsidiary Seagen (Bothell, Washington), has discontinued clinical development of PF-08052666 (SGN-MesoC2,...
EpiCure Therapeutics secures NIH grant for SLC6A1 gene therapy development
EpiCure Therapeutics, Inc., a Seattle, Washington-based Allen Institute spinout, has received a USD 1.5 million NIH R44 grant to advance an AAV gene therapy...
4DMT's 4D-150 extends durability to two years in wet AMD, challenging anti-VEGF injection dependence
4DMT's PRISM Phase IIb data support advancing 4D-150 through a broad wet AMD population, reinforcing the durability case for its lead gene therapy ahead of...
Regenxbio reports five-year durability for sura-vec ahead of pivotal wet AMD data ⭐
Regenxbio's ATMOSPHERE and ASCENT wet AMD trials—both pivotal, both fully enrolled—are set to read out topline efficacy data in the fourth quarter of 2026,...
Latigo files to IPO with non-opioid pain therapy entering late-stage development
Latigo Biotherapeutics, Inc. (Nasdaq: LTGO), a clinical-stage biopharmaceutical company developing non-opioid pain medicines, filed for an initial public...
BlossomHill files for Nasdaq IPO with EGFR-resistant lung cancer program
BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage oncology company whose lead drug candidate targets a treatment-resistant lung cancer...
DBV Tech raises USD 150m as BLA imminent for peanut-allergy patch
DBV Technologies S.A. (Euronext: DBV, Nasdaq: DBVT), a Châtillon, France-based late-stage biopharmaceutical company, has filed a refreshed at-the-market...
Vogenx seeks public funding to advance SGLT1 candidate in metabolic disorders
Vogenx, Inc. (Nasdaq: VOGX), a clinical-stage biopharmaceutical company developing a treatment for a metabolic condition with no FDA-approved therapies,...
FDA grants Fast Track designation to 4TEEN4’s invobenitug for cardiogenic shock
4TEEN4 Pharmaceuticals GmbH, headquartered in Germany, announced receipt of US FDA Fast Track Designation for invobenitug (formerly procizumab), a monoclonal antibody in…
The AllSci Brief
Free, systematic R&D and deal news. Daily.